Dyne Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Dyne Therapeutics, Inc. (DYN) reported Increase (Decrease) in Prepaid Expense and Other Assets of $23.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-07-29
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$9.48M, a 530.31% decline year-over-year.
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $32.85M.
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.20M, a 46.31% decline year-over-year.
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$389.00K.
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$986.00K, a 109.36% decline from fiscal 2024.
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $10.54M.
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$3.34M, a 180.53% decline from fiscal 2022.
- Dyne Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $4.14M, a 175.17% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $23.36M 10-Q · filed 2026-07-29 | $25.56M derived: sum of 3 quarters · filed 2026-07-29 | $25.17M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $32.85M 10-Q · filed 2026-05-11 | $35.05M derived: sum of 2 quarters · filed 2026-05-11 | $34.66M derived: sum of 3 quarters · filed 2026-05-11 | $36.86M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.81M derived: sum of 2 quarters · filed 2026-03-02 | $4.01M derived: sum of 3 quarters · filed 2026-07-29 | -$986.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | -$389.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.81M derived: sum of 2 quarters · filed 2026-07-29 | -$3.18M 10-Q · filed 2025-11-05 | $910.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$2.79M 10-Q · filed 2026-07-29 | $1.30M derived: sum of 3 quarters · filed 2026-07-29 | $534.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$5.00M 10-Q · filed 2026-05-11 | -$905.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.67M derived: sum of 3 quarters · filed 2026-05-11 | $1.47M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.33M derived: sum of 2 quarters · filed 2026-03-02 | $6.47M derived: sum of 3 quarters · filed 2026-03-02 | $10.54M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$765.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.37M derived: sum of 2 quarters · filed 2025-11-05 | $6.44M 10-Q · filed 2025-11-05 | $2.32M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $7.21M 10-Q · filed 2025-07-28 | $3.09M derived: sum of 3 quarters · filed 2026-03-02 | $8.04M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $4.07M 10-Q · filed 2025-05-08 | -$48.00K derived: sum of 2 quarters · filed 2026-03-02 | $4.91M derived: sum of 3 quarters · filed 2026-03-02 | -$657.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $838.00K derived: sum of 2 quarters · filed 2026-03-02 | -$4.73M derived: sum of 3 quarters · filed 2026-03-02 | -$3.34M 10-K · filed 2026-03-02 |
| 2023-09-30 | $4.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$609.00K derived: sum of 2 quarters · filed 2024-11-12 | $781.00K 10-Q · filed 2024-11-12 | $271.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$5.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$4.17M 10-Q · filed 2024-08-12 | -$4.68M derived: sum of 3 quarters · filed 2025-02-27 | -$687.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.39M 10-Q · filed 2024-05-02 | $880.00K derived: sum of 2 quarters · filed 2025-02-27 | $4.88M derived: sum of 3 quarters · filed 2025-02-27 | -$9.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.49M derived: sum of 2 quarters · filed 2025-02-27 | -$11.33M derived: sum of 3 quarters · filed 2025-02-27 | $4.14M 10-K · filed 2025-02-27 |
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | -$10.82M derived: sum of 2 quarters · filed 2023-10-30 | $4.65M 10-Q · filed 2023-10-30 | -$6.66M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | -$14.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $656.00K 10-Q · filed 2023-08-03 | -$10.65M derived: sum of 3 quarters · filed 2023-08-03 | -$19.23M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $15.48M 10-Q · filed 2023-05-11 | $4.17M derived: sum of 2 quarters · filed 2023-05-11 | -$4.41M derived: sum of 3 quarters · filed 2023-05-11 | $17.31M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$11.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$19.89M derived: sum of 2 quarters · filed 2023-03-02 | $1.84M derived: sum of 3 quarters · filed 2023-03-02 | $1.51M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $13.15M derived: sum of 2 quarters · filed 2022-11-03 | $12.82M 10-Q · filed 2022-11-03 | $16.16M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $21.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $21.39M 10-Q · filed 2022-08-04 | $24.74M derived: sum of 3 quarters · filed 2022-08-04 | $24.77M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$331.00K 10-Q · filed 2022-05-02 | $3.02M derived: sum of 2 quarters · filed 2022-05-02 | $3.04M derived: sum of 3 quarters · filed 2022-05-02 | $3.00M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.37M derived: sum of 2 quarters · filed 2022-03-10 | $3.33M derived: sum of 3 quarters · filed 2022-03-10 | $3.46M 10-K · filed 2022-03-10 |
| 2020-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$22.00K derived: sum of 2 quarters · filed 2021-11-04 | $107.00K 10-Q · filed 2021-11-04 | $62.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $82.00K 10-Q · filed 2021-08-05 | $37.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $129.00K 10-Q · filed 2021-05-06 | $84.00K derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $284.00K 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $329.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |